Business Medical Devices News Public Health

Changing Fortunes in the Obesity Treatment Industry

Last updated: November 30, 2011 8:21 am

PatrickDriscoll

2 Min Read

With Qnexa, Contrave and Lorcaserin each recently rejuvenated after previous FDA’s near-death sentences, the market outlook for obesity drugs is now being viewed almost as optimistically as it was in 2010.

With Qnexa, Contrave and Lorcaserin each recently rejuvenated after previous FDA’s near-death sentences, the market outlook for obesity drugs is now being viewed almost as optimistically as it was in 2010.

Devices for the treatment of obesity are on the market, aggressively promoted (to a fault) and therefore driving revenue growth for manufacturers. Much of this growth, however, comes in the vacuum left by clinical effective obesity drugs. Devices are not without complications (see “1-800-GET-THIN”) and the need for surgery, even increasingly less invasive, is an impediment to more widespread use. Long term data suggests a higher than anticipated need for repeat procedures, but this is not a significant disadvantage relative to obesity drugs, which must be taken indefinitely to maintain weight levels.

The global market for obesity drugs and devices will largely follow patterns in the Americas in general, or the U.S. in particular. Below is illustrated the 2009 to 2019 market in the Americas for obesity drugs and devices, reflecting specific anticipated market developments (see report #S835) during that time.

Source: “Products, Technologies and Markets Worldwide for the Clinical Management of Obesity, 2011-2019.” Report #S835, MedMarket Diligence, LLC

TAGGED:obesity obesity drugs obesity treatment

Share This Article

By PatrickDriscoll

Follow:

I serve the interests of medical technology company decision-makers, venture-capitalists, and others with interests in medtech producing worldwide analyses of medical technology markets for my audience of mostly medical technology companies (but also rapidly growing audience of biotech, VC, and other healthcare decision-makers). I have a small staff and go to my industry insiders (or find new ones as needed) to produce detailed, reality-grounded analyses of current and potential markets and opportunities. I am principally interested in those core clinical applications served by medical devices, which are expanding to include biomaterials, drug-device hybrids and other non-device technologies either competing head-on with devices or being integrated with devices in product development. The effort and pain of making every analysis global in scope is rewarded by my audience's loyalty, since in the vast majority of cases they too have global scope in their businesses.Specialties: Business analysis through syndicated reports, and select custom engagements, on medical technology applications and markets in general/abdominal/thoracic surgery, interventional cardiology, cardiothoracic surgery, patient monitoring/management, wound management, cell therapy, tissue engineering, gene therapy, nanotechnology, and others.